← All Valneva SE filings

Valneva SE 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
VALN
Valneva SE
20-F: Valneva SE Reports Full Year 2024 Results, Highlights Progress on Key Vaccine Programs
Valneva SE's 20-F filing summarizes the company's financial results for 2024 and provides updates on its vaccine development and commercialization activities, including IXCHIQ, Lyme disease vaccine candidate VLA15, and Shigella vaccine candidate S4V2.
NASDAQ
VALN
Valneva SE
20-F: Valneva Secures Key Contract, Navigates Financial Landscape with Strategic Debt Management and Pipeline Advancement
Valneva reports financial results, secures a key supply contract, and strategically manages debt while advancing its vaccine pipeline, including IXCHIQ and Lyme disease candidate VLA15.